Sociodemographic determinants of catch-up HPV vaccination completion between 2016-2019 in Norway

Abstract Background College-aged women and men are at increased risk of acquiring human papillomavirus (HPV) and are considered an important catch-up population for HPV vaccination. Technology provides an attractive platform for HPV vaccination interventions. Limited research has explored technology-mediated HPV vaccination awareness interventions aimed at college students. The purpose of this pilot study was to evaluate a novel, technology-mediated, social media-based intervention to promote HPV vaccination among college students.Methods A controlled, quasi-experimental, mixed methods study examined the feasibility of a technology-based intervention among two undergraduate classes (n = 58) at a public university in the southeastern United States of America. Classes were randomized by coin flip to receive one of two cancer prevention programs (i.e., HPV vaccination [intervention] or healthy weight [control]). Both programs contained eight technology-mediated health promotion sessions, including weekly emails and private Facebook group posts. Participants completed a pre- and post-test web-based survey and submitted weekly qualitative reflections. Data were analyzed using descriptive statistics for quantitative data and thematic review for qualitative data.Results Knowledge of HPV and HPV vaccination improved among participants in the HPV vaccination intervention relative to those in the control condition. Participants (97%) interacted on Facebook by “liking” a post or comment or posting a comment. Participants reported that Facebook was easy to use and encouraged interaction, which contributed to the success of the intervention.Conclusion Participants demonstrated robust engagement and high treatment satisfaction. Objective measures and qualitative open-ended assessment of the intervention showed high levels of engagement with the electronic newsletters and Facebook group. This pilot study suggests that social media is an effective platform to reach college students with health promotion interventions and increase HPV vaccination awareness in this important catch-up population.

Download Full-text

Catch-up HPV Vaccination and Subsequent Uptake of Papanicolaou Testing in A State-mandated Health System

Cancer Prevention Research ◽

10.1158/1940-6207.capr-20-0570 ◽

2021 ◽

Vol 14 (4) ◽

pp. 415-420

Author(s):

Gabriel Chodick ◽

Amy E. Leader ◽

Sharon Larson

Keyword(s):

Health System ◽

Hpv Vaccination ◽

Catch Up

Download Full-text

Evaluating Risk-Stratified HPV Catch-up Vaccination Strategies: Should We Go beyond Age 26?

Medical Decision Making ◽

10.1177/0272989x211042894 ◽

2021 ◽

pp. 0272989X2110428

Author(s):

Fan Wang ◽

Kristen N. Jozkowski ◽

Shengfan Zhang

Keyword(s):

Simulation Model ◽

Clinical Outcomes ◽

Risk Model ◽

Hpv Vaccination ◽

The United States ◽

Gradient Boosting ◽

Transmitted Infection ◽

Extreme Gradient Boosting ◽

Catch Up ◽

The Impact

Background Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States. HPV can cause genital warts and multiple types of cancers in females. HPV vaccination is recommended to youth age 11 or 12 years before sexual initiation to prevent onset of HPV-related diseases. For females who have not been vaccinated previously, catch-up vaccines are recommended through age 26. The extent to which catch-up vaccines are beneficial in terms of disease prevention and cost-effectiveness is questionable given that some women may have been exposed to HPV before receiving the catch-up vaccination. This study aims to examine whether the cutoff age of catch-up vaccination should be determined based on an individual woman’s risk characteristic instead of a one-size-fits-all age 26. Methods We developed a microsimulation model to evaluate multiple clinical outcomes of HPV vaccination for different women based on a number of personal attributes. We modeled the impact of HPV vaccination at different ages on every woman and tracked her course of life to estimate the clinical outcomes that resulted from receiving vaccines. As the simulation model is risk stratified, we used extreme gradient boosting to build an HPV risk model estimating every woman’s dynamic HPV risk over time for the lifetime simulation model. Results Our study shows that catch-up vaccines still benefit all women after age 26 from the perspective of clinical outcomes. Women facing high risk of HPV infection are expected to gain more health benefits compared with women with low HPV risk. Conclusions From a cancer prevention perspective, this study suggests that the catch-up vaccine after age 26 should be deliberately considered.

Download Full-text